Evgeny Voronin

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study

Kathleen Squires, Cissy Kityo, Sally Hodder et al. · The Lancet HIV · 2016 · 84 citations · Full text

Pharmacy, Pharmacotherapy, Hiv Prevention +14

Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

Cissy Kityo, Debbie Hagins, Ellen Koenig et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 56 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Pedro Cahn, Richard Kaplan, Paul E. Sax et al. · The Lancet HIV · 2017 · 35 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Rapid HIV testing and prevention of perinatal HIV transmission in high-risk maternity hospitals in St. Petersburg, Russia

Dmitry M. Kissin, Natalia Akatova, Aza Rakhmanova et al. · American Journal of Obstetrics and Gynecology · 2008 · 27 citations

Public Health, Maternal Health, Obstetrics +17